Type 2 Diabetes Treatment Invokamet XR Awaits FDA Action

Article

Janssen Research and Development LLC has submitted a new drug application to the FDA for canagliflozin and metformin hydrochloride extended release (Invokamet XR).

Janssen Research and Development LLC has submitted a new drug application to the FDA for canagliflozin and metformin hydrochloride extended release (Invokamet XR).

The once-daily 2 tablets are designed to treat type 2 diabetes in adults as an adjunctive treatment to diet and exercise to improve glycemic control.

“This submission to the FDA is evidence of Janssen’s continued commitment to bringing forth new treatment options for people with type 2 diabetes,” said James List, global therapeutic area head of Cardiovascular and Metabolism at Janssen, in a press release. “We look forward to working with the FDA to bring this combination therapy to adult patients with type 2 diabetes in need of new options.”

Invokamet, the first fixed-dose combination tablet to combine canagliflozin and immediate release metformin hydrochloride, received approval from the FDA back in 2014.

Adverse effects associated with the treatment include lactic acidosis and dehydration.

Related Videos
male pharmacist using digital tablet during inventory in pharmacy | Image Credit: sofiko14 - stock.adobe.com
Pharmacist holding medicine box in pharmacy drugstore. | Image Credit: I Viewfinder - stock.adobe.com
Pharmacy Drugstore Checkout Cashier Counter | Image Credit: Gorodenkoff - stock.adobe.com
Medicine tablets on counting tray with counting spatula at pharmacy | Image Credit: sutlafk - stock.adobe.com
Capsules medicine and white medicine bottles on table | Image Credit: Satawat - stock.adobe.com
Human cell or Embryonic stem cell microscope background | Image Credit: Anusorn - stock.adobe.com
Concept of health care, pharmaceutical business, drug prices, pharmacy, medicine and economics | Image Credit: Oleg - stock.adobe.com
Biosimilar pharmaceutical drug bottle on blue background. | Image Credit: Carl - stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.